Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male or female participants ≥1 years old at Visit 1.~* Participants and/or a legally acceptable representative/parent/legal guardian are willing and able to comply with all scheduled visits, vaccination plan, and other study procedures including completion of the e-diary for 7 days for participants after each of 3 vaccinations.~* Participants and/or a legally acceptable representative/parent/legal guardian must be able to be contacted by telephone during study participation.~* Participants and/or a legally acceptable representative/parent/legal guardian are capable of giving signed informed consent.~Exclusion Criteria:~* Major known congenital malformation or serious chronic disorder.~* Known history of TBEV infection.~* Known history of other flavivirus infection (eg, dengue fever, yellow fever, JEV, West Nile virus).~* Known history of infection with HIV, HCV, or HBV.~* Immunocompromised participants with known or suspected immunodeficiency.~* History of autoimmune disease or an active autoimmune disease requiring therapeutic intervention.~* Previous vaccination with any licensed or investigational TBE vaccine, or planned receipt of other flavivirus vaccines apart from JEV vaccine (eg, yellow fever, dengue fever) during the study. Administration of JEV vaccine is prohibited during participation.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ≥16 Years Old (Type: EXPERIMENTAL): TBE vaccine 0.5 mL (intramuscular injection).
- 1 to <16 Years Old (Type: EXPERIMENTAL): TBE vaccine 0.25ｍL (intramuscular injection).

Based on this trial design, predict the completion outcome and termination type (if applicable).